Nektar Therapeutics Set to Join Investor Conference
Nektar Therapeutics (NASDAQ: NKTR) has exciting news that it will be participating in the upcoming H.C. Wainwright 3rd Annual BioConnect Investor Conference. This event will take place at the Nasdaq Headquarters and promises to be a valuable opportunity for investors and stakeholders.
Conference Details
The conference will feature a webcast of Nektar's participation. This session is scheduled for Tuesday and will begin at 1:30 p.m. Eastern Time, which is 10:30 a.m. Pacific Time. It will be an exciting presentation where insights into Nektar's innovative approaches to immunotherapeutics will be shared.
Webcast Access and Replay
The fireside chat will be available through the webcast link provided by Nektar Therapeutics. Additionally, attendees looking for more information can find it in the Investor Events section of their website. A convenient replay of the presentation will also be accessible for 30 days, allowing for flexibility for those who cannot attend live.
One-on-One Meetings Available
During the conference, Nektar encourages investors to request one-on-one meetings with company management. This is a great opportunity to delve deeper into Nektar's operations and innovations directly from the leadership team. Interested individuals should reach out to their respective H.C. Wainwright representatives to arrange such meetings.
About Nektar Therapeutics
Nektar Therapeutics is not just another biotech company. It is a clinical-stage firm focused on developing treatments that address significant immunological dysfunctions associated with autoimmune diseases and chronic inflammatory conditions. The company’s leading candidate, rezpegaldesleukin (REZPEG or NKTR-358), is groundbreaking as a first-in-class regulatory T cell stimulator.
Nektar is advancing in its clinical trials, with two Phase 2b studies underway: one for atopic dermatitis and another aimed at alopecia areata. Moreover, the firm's pipeline encompasses a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody alongside bispecific programs known as NKTR-0165 and NKTR-0166. Another notable product is NKTR-422, a modified hematopoietic colony-stimulating factor (CSF) protein, designed to enhance immune response.
In addition to their internal developments, Nektar collaborates with various partners to evaluate NKTR-255. This investigational IL-15 receptor agonist is gaining attention for its potential to significantly boost the immune system's effectiveness in fighting cancer. With ongoing clinical trials, Nektar Therapeutics is well-positioned to make substantial contributions to the field of immunotherapy.
Contact Information
For those interested in more details or inquiries, the company has made available a dedicated contact:
For Investors:
Ahu Demir, Ph.D.
LifeSci Advisors, LLC
Phone: 212-915-3820
For Media:
Madelin Hawtin
LifeSci Communications
Phone: 603-714-2638
Frequently Asked Questions
What is the BioConnect Investor Conference?
The BioConnect Investor Conference is an annual event where biotechnology companies present their latest innovations to potential investors and stakeholders.
When will Nektar's presentation take place?
Nektar is scheduled to present on Tuesday at 1:30 p.m. Eastern Time during the conference.
How can I access the conference webcast?
The webcast can be accessed via the Nektar Therapeutics website during the presentation, with a replay available for 30 days.
What is Nektar’s leading product candidate?
Nektar's prominent candidate is rezpegaldesleukin (REZPEG or NKTR-358), which targets autoimmune and chronic inflammatory diseases.
Can investors meet with Nektar management at the conference?
Yes, investors can request one-on-one meetings with company management by contacting their H.C. Wainwright representative.
